Company Interview / 4D Medical (ASX:4DX) Investor Presentation

Andreas Fouras of 4D Medical (ASX:4DX) shares that the company has built a leading global position in cardiothoracic imaging software, supported by a substantial portfolio of 100 patented technologies and nine FDA-approved imaging products. Fouras highlights the third-generation flagship, CT:VQ, which enables clinicians to evaluate both airflow and blood flow in the lungs from routine CT scans—without the use of injected or inhaled radioactive contrast agents. This approach not only streamlines the clinical workflow but also reduces patient inconvenience, as it eliminates the need for multiple appointments and radioactive exposure required in traditional nuclear VQ imaging.

Fouras states that 4DMedical’s technology aims to disrupt the $1 billion US nuclear VQ imaging market by offering hospitals a faster, scalable alternative due to the greater prevalence of CT scanners over nuclear scanners. Reimbursement structures are also positioned to benefit providers, with significantly higher revenue per minute possible when using CT:VQ, compared to nuclear imaging. Hospitals and departments can also reallocate nuclear imaging resources to higher-value tests, increasing economic efficiency across the board.

In terms of commercial traction, Fouras points to the first hospital order from Stanford Medical and increasing leads generated, particularly among 300 existing US hospital customers and 50 top academic medical centres. 4DMedical (ASX:4DX) sees further expansion potential in large-scale Veterans Affairs contracts, especially with new US administration support.

You should be aware that companies presenting do so under commercial agreement with AUSBIZ CAPITAL PTY LTD